Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_assertion type Assertion NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_head.
- NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_assertion description "[The production of IFN-? and TNF-? by CD4(+) and CD8(+) T lymphocytes from patients with lower-risk MDS could be enhanced by recombinant human IL-17 (rhIL-17) treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_provenance.
- NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_assertion evidence source_evidence_literature NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_provenance.
- NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_assertion SIO_000772 23331180 NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_provenance.
- NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_assertion wasDerivedFrom befree-20140225 NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_provenance.
- NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_assertion wasGeneratedBy ECO_0000203 NP442545.RAjclza1wKXf7syX6NiZyip4Vr5GN-4bVP4O-VU613HJ0130_provenance.